Correction to: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials (Leukemia, (2024), 38, 3, (475-481), 10.1038/s41375-024-02159-0)

Abstract

Correction to: Leukemiahttps://doi.org/10.1038/s41375-024-02159-0, published online 29 January 2024 Following publication of the article, the authors realized that several data points in Figure S3B and the accompanying manuscript text were incorrect. This oversight has been addressed and the corrected figure has been added. Supplementary information, Figure S3B: The percentage of patients with grade 3-4 TE-AOEs from the PACE CP-CML group was inaccurately rounded to 12%; the correct percentage is 11%. In addition, we have corrected the error in the manuscript on page 477 in the Safety outcomes section. The revised statement is below:Grade 3-4 TE-AOEs were 11% in PACE and 5% in OPTIC, and serious TE-AOEs were 15% in PACE and 4% in OPTIC (Fig. S3). Supplementary information, Figure S3B: The number of patients with serious TE-AOEs in the PACE CP-CML group was cited incorrectly as 9; the correct number of patients is 40. Supplementary information, Figure S3B: The percentage of patients with grade 3-4 TE-AOEs from the PACE CP-CML group was inaccurately rounded to 12%; the correct percentage is 11%. In addition, we have corrected the error in the manuscript on page 477 in the Safety outcomes section. The revised statement is below: Grade 3-4 TE-AOEs were 11% in PACE and 5% in OPTIC, and serious TE-AOEs were 15% in PACE and 4% in OPTIC (Fig. S3). Supplementary information, Figure S3B: The number of patients with serious TE-AOEs in the PACE CP-CML group was cited incorrectly as 9; the correct number of patients is 40. The corrected figure S3B is now included in the supplementary information. The original article has been corrected.